SUBSCRIBE
SUBSCRIBE

Apnimed

NEWS
American dollars grow on the garden bed on a meadow
Drug Development
Money on the Move: April Showers Bring May Flowers—and Funding
Dianthus Therapeutics, Enavate Sciences and CytoTronics were all launched with this recent wave of investor funding. For that and more, continue reading.
May 4, 2022
 · 
4 min read
 · 
Hannah Chudleigh
JOBS
IN THE PRESS
Drug Development
Apnimed Announces First Patient Dosed in LunAIRo, the First Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
September 21, 2023
 · 
5 min read
Drug Development
Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs
September 18, 2023
 · 
4 min read
Drug Development
Apnimed to Present New Data on Investigational Oral Therapies for Obstructive Sleep Apnea at ERS International Congress 2023
September 6, 2023
 · 
4 min read
Genetown
APNIMED to Participate in Upcoming Investor Conferences in September 2023
August 30, 2023
 · 
3 min read
Genetown
Fierce Biotech Names Apnimed a 2023 “Fierce 15” Biotech Company
August 28, 2023
 · 
4 min read
Genetown
APNIMED to Participate in the 43rd Annual Canaccord Genuity Global Growth Conference
August 1, 2023
 · 
3 min read
Genetown
Apnimed to Participate in the William Blair Virtual Conference: Transitioning Biotech Breakthroughs to Commercial Success
July 12, 2023
 · 
3 min read
Genetown
Apnimed to Participate in the 2023 BIO International Convention
May 23, 2023
 · 
3 min read
Drug Development
Apnimed Presented Positive Phase 2b Results on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea, for the First Time at ATS 2023
May 21, 2023
 · 
7 min read
Drug Development
Apnimed to Present Positive Phase 2b Results on AD109, an Investigational Oral Treatment for Obstructive Sleep Apnea, at ATS 2023
May 15, 2023
 · 
5 min read
Load More